7 Undervalued Biotechnology & Medical Research Stocks for Thursday, June 22
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Thursday, June 22 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Commentary & Analysis
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, January 24
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, January 24 based on AAII’s Stock Grades.Jenna Brashear
Is XORTX Therapeutics Inc (XRTX) Stock a Good Investment?
Learn more about XORTX Therapeutics Inc's (XRTX) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | XRTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.0 | $589.9 | 2% |
|
| Shares Out (Mil) | 1.6 | 43.1 | 6% |
|
| Institutional Ownership | 88.3% | 83.7% | 56% |
|
| Float (Mil) | 1.8 | 45.1 | 5% |
|
| Beta | 0.08 | 0.73 | 8% |
|
| Avg Daily Volume (000s) | 425 | 300 | 57% |
|
| Price Change (52-week) |
(61.2%) | 65.3% | 13% |
|
| Growth | XRTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (22.0%) | (1.4%) | 18% |
|
| EPS (5yr) | 16.3% | 15.1% | 60 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (33.5%) | (15.0%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XRTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($4) | ($11) | 34% |
|
| EPS (TTM) | ($2.825) | ($0.700) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($6) | 25% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $5 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $3 | $508 | 4% |
|
| Valuation | XRTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.52 | 2.51 | 9% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | XRTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (83.8%) | (22.5%) | 7% |
|
| ROE | (99.2%) | (21.8%) | 9% |
|
| Liabilities to Assets | 11.0% | 32.5% | 6% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 9/17/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 0.9% |
| +/- S&P 500: | -6.6 |
